A clinical scoring tool validated with machine learning for predicting severe hand–foot syndrome from sorafenib in hepatocellular carcinoma

[1]  Jennifer M. Taber,et al.  Translating Cancer Risk Prediction Models into Personalized Cancer Risk Assessment Tools: Stumbling Blocks and Strategies for Success , 2020, Cancer Epidemiology, Biomarkers & Prevention.

[2]  Aung Ko Win,et al.  A New Comprehensive Colorectal Cancer Risk Prediction Model Incorporating Family History, Personal Characteristics, and Environmental Factors , 2020, Cancer Epidemiology, Biomarkers & Prevention.

[3]  S. Terai,et al.  Effective prevention of sorafenib-induced hand–foot syndrome by dried-bonito broth , 2018, Cancer management and research.

[4]  N. Syn,et al.  Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine–Induced Hand-Foot Syndrome: A Randomized Clinical Trial , 2017, JAMA oncology.

[5]  D. Révész,et al.  Decision support systems for incurable non-small cell lung cancer: a systematic review , 2017, BMC Medical Informatics and Decision Making.

[6]  Z. Younossi,et al.  Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities , 2017, Medicine.

[7]  M. Naito,et al.  Hemoglobin Value Is the Most Important Factor in the Development of Hand-Foot Syndrome under the Capecitabine Regimen , 2016, Chemotherapy.

[8]  M. Kudo,et al.  Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  T. Habuchi,et al.  Risk factors for sorafenib-induced high-grade skin rash in Japanese patients with advanced renal cell carcinoma , 2013, Anti-cancer drugs.

[10]  O. Mir,et al.  Variability of sorafenib toxicity and exposure over time: a pharmacokinetic/pharmacodynamic analysis. , 2012, The oncologist.

[11]  F. Lang,et al.  Enhanced Erythrocyte Membrane Exposure of Phosphatidylserine Following Sorafenib Treatment: An in vivo and in vitro Study , 2012, Cellular Physiology and Biochemistry.

[12]  M. Lacouture,et al.  Development and validation of a prediction index for hand-foot skin reaction in cancer patients receiving sorafenib. , 2012 .

[13]  I. Betlloch,et al.  Severe sorafenib-induced hand-foot skin reaction. , 2011, Dermatology online journal.

[14]  M. Alter,et al.  The hand‐foot‐syndrome associated with medical tumor therapy – classification and management , 2010, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[15]  S. Baker,et al.  Interaction of the Multikinase Inhibitors Sorafenib and Sunitinib with Solute Carriers and ATP-Binding Cassette Transporters , 2009, Clinical Cancer Research.

[16]  C. Robert,et al.  Dermatologic symptoms associated with the multikinase inhibitor sorafenib. , 2009, Journal of the American Academy of Dermatology.

[17]  H. Ishwaran.  Variable importance in binary regression trees and forests , 2007, 0711.2434.

[18]  X-p Chen,et al.  Long‐term outcome of resection of large hepatocellular carcinoma , 2006, The British journal of surgery.

[19]  Sanjay Kumar,et al.  Free heme toxicity and its detoxification systems in human. , 2005, Toxicology letters.

[20]  C. N. Coleman,et al.  CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. , 2003, Seminars in radiation oncology.

[21]  J. Eaton,et al.  Haem, haem oxygenase and ferritin in vascular endothelial cell injury. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[22]  P. Oliveira,et al.  Neutrophil activation by heme: implications for inflammatory processes. , 2002, Blood.

[23]  F. Harrell,et al.  Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .